Stereotactic radiosurgery (SRS) for brain metastases: a systematic review

Carsten Nieder1*, Anca L Grosu2 and Laurie E Gaspar3

Abstract

In many patients with brain metastases, the primary therapeutic aim is symptom palliation and maintenance of neurologic function, but in a subgroup, long-term survival is possible. Local control in the brain, and absent or controlled extracranial sites of disease are prerequisites for favorable survival. Stereotactic radiosurgery (SRS) is a focal, highly precise treatment option with a long track record. Its clinical development and implementation by several pioneering institutions eventually rendered possible cooperative group randomized trials. A systematic review of those studies and other landmark studies was undertaken. Most clinicians are aware of the potential benefits of SRS such as a short treatment time, a high probability of treated-lesion control and, when adhering to typical dose/volume recommendations, a low normal tissue complication probability. However, SRS as sole first-line treatment carries a risk of failure in non-treated brain regions, which has resulted in controversy around when to add whole-brain radiotherapy (WBRT). SRS might also be prescribed as salvage treatment in patients relapsing despite previous SRS and/or WBRT. An optimal balance between intracranial control and side effects requires continued research efforts.

Keywords: Brain metastases, Radiation treatment, Radiotherapy, Stereotactic radiosurgery

Historically, treatment options for patients with brain metastases from solid tumors were limited to surgery and/or whole-brain radiotherapy (WBRT) supported by corticosteroids if indicated, with few systemic therapies available that were able to impact on extracranial metastases. Therefore, median survival after non-surgical management typically was in the range of 3-4 months [1]. Both intra- and extracranial disease progression was common, resulting in complex clinical situations with components of decreasing performance status (PS), neurological status, and impaired organ function, e.g. from liver and lung metastases. Few patients who relapsed in the brain received salvage treatment such as reirradiation [2,3]. Partial brain fields or repeat WBRT were available but the efficacy of these salvage attempts was modest [4]. There was an urgent need for new treatment approaches, and among several avenues of research, clinical implementation of single fraction stereotactic radiosurgery (SRS) during the 1980s probably was the single most important innovation. The neurosurgery field gets credit for the early exploration of SRS [5-7], but the evolution of imaging, radiation treatment planning and delivery technology had to occur before several dedicated research groups were able to safely deliver SRS to patients with brain metastases [8-11]. The present review, which is based on a well defined method for identification of relevant studies, focuses on recent developments.

Methods

A systematic search of the citation database Scopus (Elsevier B.V., www.scopus.com) by use of the terms ‘stereotactic AND brain’ and ‘radiosurgery’ was performed on 17th January 2014. We did not use more specific search terms in order to avoid missing relevant publications. Articles were selected irrespective of language, year of publication and article type (review, guideline, clinical study, experimental study etc.), as described previously [12]. In order to determine whether or not a given article reported on SRS for brain metastases we accessed its abstract. Then, all articles dealing with the subject of this review were ranked by number of citations (field ‘times cited’ in the Scopus citation database) in order to create a list of articles with the highest number of citations, referred to as landmark studies (list available on
request from the corresponding author). The top 50 articles were reviewed for contents, study type (phase I, II, III, retrospective etc.) and outcomes. Given that such hitlists are dominated by older publications because recent articles are less likely to have accumulated high numbers of citations [13], separate searches were performed that covered the years 2011 and 2012, respectively. The authors also used their reference lists from previous reviews [14-17] to cross-check for important studies that might not have been cited as often as expected. In addition, on 22nd March 2014 the database Medline/PubMed was searched by the two terms mentioned above.

Results and discussion
Table 1 contains the 25 most-cited articles [18-42]. These were published between 1990 and 2010. Of these, the prospective randomized clinical trials acquired the highest numbers of citations per year [18-20]. Most clinically relevant aspects of SRS for brain metastases are represented in the table, including the role of SRS alone compared to SRS plus WBRT, the role of WBRT alone compared to WBRT plus SRS, the role of SRS compared to surgery, patient selection based on prognostic models, SRS for recurrent disease, radiobiology of SRS, and toxicity. Issues related to the outcomes of different treatment planning approaches and treatment units ranked among the top 50 rather than the top 25 articles [10,43-66]. The most cited publications from the year 2011 did not cover any new aspects [67-71]. However the 2012 articles focused on new topics such as SRS to resection cavities in the postoperative setting, SRS in patients with more than 4 brain metastases, and new systemic treatments in addition to SRS [72-76]. Fractionated stereotactic radiotherapy was not among the most-cited topics.

We will not discuss postoperative SRS in great detail, because this investigational approach so far is not yet supported by randomized trials [76]. Phase 2 data suggests that postoperative SRS is associated with high rates of local control, especially for non-superficial brain metastases of limited size (<3 cm) [77]. Metastases ≥3 cm

| Authors and year of publication | Study description | Absolute citation count | Citations per year |
|---------------------------------|-------------------|-------------------------|--------------------|
| Andrews et al. 2004 [18]        | RTOG 9508 randomised trial | 812 | 81 |
| Aoyama et al. 2006 [19]         | SRS ± WBRT randomised trial | 527 | 66 |
| Kondziolka et al. 1999 [20]     | WBRT ± SRS randomised trial | 517 | 37 |
| Flickinger et al. 1994 [21]     | SRS for solitary BM, multi institutional | 445 | 22 |
| Shaw et al. 2000 [22]           | RTOG protocol 90-05 | 393 | 28 |
| Alexander et al. 1995 [23]      | Retrospective study | 377 | 21 |
| Auechter et al. 1996 [24]       | SRS for resectable single BM, multi institutional | 344 | 20 |
| Chang et al. 2009 [25]          | SRS ± WBRT randomised trial | 314 | 63 |
| Sneed et al. 2002 [26]          | SRS ± WBRT, multi institutional | 286 | 26 |
| Sneed et al. 1999 [27]          | SRS ± WBRT, single institution | 286 | 20 |
| Pirzkall et al. 1998 [28]       | SRS ± WBRT, single institution | 229 | 15 |
| Sperduto et al. 2008 [29]       | Prognostic score, incl. RTOG 95-08 data | 216 | 36 |
| Mehta et al. 1992 [30]          | Prospective single arm, n = 40 | 186 | 9 |
| Bindal et al. 1996 [31]         | SRS vs. resection | 182 | 10 |
| Engenhart et al. 1993 [32]      | Retrospective study | 178 | 9 |
| Mori et al. 1998 [33]           | SRS for melanoma BM | 169 | 11 |
| Hall & Brenner 1993 [34]        | Radiobiology of SRS | 169 | 8 |
| Shiu et al. 1997 [35]           | Local control after SRS | 165 | 10 |
| Aoyama et al. 2007 [36]         | Neurocognitive outcome, randomised trial | 163 | 23 |
| Muacevic et al. 1999 [37]       | SRS vs. resection | 163 | 11 |
| Chao et al. 2001 [38]           | Radionecrosis vs. relapse after SRS | 161 | 12 |
| Adler et al. 1992 [39]          | Retrospective study | 161 | 8 |
| Sanghavi et al. 2001 [40]       | Multi institutional, stratified for prognosis | 156 | 12 |
| Sperduto et al. 2010 [41]       | Prognostic score, diagnosis specific | 155 | 39 |
| O’Neill et al. 2003 [42]        | SRS vs. resection | 155 | 14 |

RTOG: Radiation Therapy Oncology Group, SRS: stereotactic radiosurgery, WBRT: whole-brain radiotherapy, BM: brain metastases.
with superficial dural/pial involvement demonstrated the highest risk of local failure. In a different study, patients with breast cancer had the highest risk of leptomeningeal progression following SRS (24% at 1 year) [78]. Head to head comparisons of SRS to other types of postoperative radiotherapy, including WBRT, are needed to conclusively evaluate the pros and cons of SRS in this setting.

Some institutions have more than 25 years of experience with SRS and have collected data on thousands of patients, often transferred to multi institutional databases. A recent Japanese multi institutional prospective study included 1194 patients (76% with lung cancer) [79]. Its aim was to examine whether survival after SRS without WBRT as initial treatment for patients with 5-10 brain metastases (median 6) was non-inferior to that of patients with 2-4 lesions. Size limits were metastases <3 cm in longest diameter, largest tumor <10 ml in volume, and total cumulative volume \( \leq 15 \) ml. Median survival was longest in patients with one lesion (n = 455, 13.9 months). But patients with 2-4 lesions had comparable survival to patients with 5-10 lesions (median survival 10.8 months, hazard ratio 0.97, 95% confidence interval 0.81-1.18). This met the pre-specified definition of non-inferiority, despite the development of new lesions in >60% of patients. Further salvage SRS was done in more than 40%, and 9% received salvage WBRT. The delivery of further SRS or WBRT was not significant different between the groups. Grade 3-4 adverse events occurred in up to 3% of patients in each group. Only 8% of patients died from their brain disease.

As displayed in Table 2, SRS achieves high rates of local progression-free survival of SRS-treated lesions and its efficacy may be less influenced by histology or radiosensitivity than that of fractionated radiotherapy [63]. At the same time, severe complications are observed in a minority of patients. This is the primary reason for many institutions to expand its utilization beyond the initial target population, which often was defined as those with 1-3 lesions. The Japanese study [79] suggests that SRS is reasonable for patients with up to 10 lesions. However, it is also known that number of initial lesions predicts the risk for development of new metastases and thus need for salvage treatment (new course of SRS or WBRT). Primary tumor type and extracranial disease status also impact on distant brain failure risk. Based on these three predictors, a nomogram was recently developed (n = 464 patients) [80]. Table 3 shows examples calculated according to this model, which should be validated further.

Post-SRS adjuvant WBRT reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival [67,84]. The major obstacle against the general adoption of combined SRS and WBRT is the fear of neurocognitive decline after WBRT. Patients with limited survival expectation because of progressive, uncontrollable extracranial disease should be managed with WBRT or best supportive care rather than SRS [85,86].

**First line SRS and the controversy around whole-brain radiotherapy**

Focal treatment such as SRS, improves the local control observed with WBRT. In a small randomized study primarily addressing this endpoint, patients with 2-4 brain metastases (all \( \leq 25 \) mm diameter) either received WBRT alone (30 Gy in 12 fractions) or WBRT plus SRS [20]. The study was stopped at an interim evaluation following accrual of just 27 patients. The rate of local failure at 1 year was 100% after WBRT alone but only 8% in patients who had boost SRS. In exploratory analysis, patients who received WBRT alone lived a median of 7.5 months, while those who received WBRT plus RS lived 11 months (p = 0.22). With only 27 patients, possible survival differences cannot be adequately assessed. A different randomized study by the Radiation Therapy Oncology Group (RTOG) enrolled 333 patients with 1-3 brain metastases [18]. Maximum diameter of the largest lesion was 4 cm and additional lesions could not exceed 3 cm. Minimum

### Table 2 Results of stereotactic radiosurgery (SRS) for brain metastases

| Reference                  | n (patients/lesions) | Prescribed dose (median; range [Gy])* | Median OS (m) | 1-year PFS (%) |
|----------------------------|----------------------|---------------------------------------|---------------|----------------|
| Pirzkall et al. 1998 [28]  | 236/311              | 20; 10-30                             | 5.5           | 89             |
| Cho et al. 1998 [81]       | 73/136               | 17.5; 6-50                            | 7.8           | 80             |
| Sneed et al. 1999 [27]     | 62/118c              | 18; 15-22                             | 11.3          | 80             |
| Varlotto et al. 2003 [82]  | 43/117f              | 17.5; 15-22                           | 11.1          | 86             |
| Andrews et al. 2004 [18]   | 164/269f             | Not given; 15-24                       | 6.5           | 82             |
| Bhatnagar et al. 2006 [83] | 205/4-18 lesions eachg | 16; 12-20                             | 8.0           | 71             |

OS: overall survival in months; PFS: progression-free survival.

*Prescription isodose or point varied, some series included SRS plus WBRT.

**SRS only.

aSRS plus WBRT (no significant difference in OS and PFS between both groups).

bSRS plus WBRT.

cSRS plus/minus WBRT.
Karnofsky PS was 70. WBRT dose was 37.5 Gy in 15 fractions in both groups. SRS boost dose was adjusted to lesion size (24 Gy, 18 Gy and 15 Gy for lesions < 2 cm, > 2 cm but less than 3 cm, and > 3 cm but < 4 cm, respectively). Median survival was significantly better after SRS boost in patients with single brain metastasis. By multivariate analysis, survival was also improved in recursive partitioning analysis (RPA) class I patients (RPA details are provided in Table 4). SRS-treated patients were more likely to have a stable or improved PS at 6 months (43% vs 27%, p = 0.03). Central imaging review showed higher response rates at 3 months and better control of the treated lesions at 1 year, p = 0.01. The risk of developing a local recurrence was 43% greater with WBRT alone. The addition of temozolomide or erlotinib did not improve survival after WBRT and SRS in another randomized RTOG trial, which included only patients with non-small cell lung cancer [87].

After many years of controversy about the role of combining WBRT with SRS and considerable variation in practice [27,28], a Japanese group completed a prospective randomized multicenter phase III study of SRS alone vs combined SRS and WBRT [19]. The primary endpoint was survival with an expected difference of 30%. The trial included adult patients with Karnofsky PS >60 and a maximum of 4 brain metastases, none exceeding 3 cm diameter. The patients were stratified by number of lesions (1 vs 2-4), extracranial tumor activity (activ vs stable, i.e. controlled for at least 6 months), and primary tumor (lung cancer vs others). WBRT was given in 10 fractions of 3 Gy. SRS dose varied with size of the lesion (up to 2 cm: 22-25 Gy, >2 cm: 18-20 Gy margin dose), and was reduced by 30% if WBRT was given. The mean dose was 21.9 Gy in the SRS alone arm and 16.6 Gy in the combined arm. The combined arm contained 65 patients, the SRS arm 67 patients. Almost 50% of patients had a single lesion. The SRS group contained slightly more patients with PS 90-100% (66 vs 52%) and patients without neurological symptoms (70 vs 59%). However, the differences were not statistically significant. Median survival was 7.5 months after SRS plus WBRT and 8 months after SRS alone. One-year survival in the combined treatment arm was increased by 36%, but was not statistically significantly different, possibly due to low patient numbers (38.5 vs 28.4%, p > 0.05). There was no significant difference in the percentage of patients that died from predominantly neurologic causes (23 vs 19%). Age, PS, extracranial disease activity and status of the primary tumor were significant prognostic factors on multivariate analysis. After SRS alone, 2 patients developed serious late complications.

### Table 3 Estimates of 6-month survival without distant brain failure based on a new nomogram [80]

| Primary tumor type | 1-3 BM, stable systemic disease | 1-3 BM, progressive systemic disease | 4-13 BM, stable systemic disease | 4-13 BM, progressive systemic disease |
|--------------------|---------------------------------|-------------------------------------|---------------------------------|-------------------------------------|
| Renal cell cancer  | 69%                             | 67%                                 | 48%                             | 46%                                 |
| Malignant melanoma | 57%                             | 55%                                 | 32%                             | 30%                                 |
| Lung, adeno ca     | 74%                             | 72%                                 | 55%                             | 53%                                 |
| Lung, squamous ca  | 58%                             | 57%                                 | 33%                             | 32%                                 |
| Breast, Her-2 positive | 73%                         | 72%                                 | 53%                             | 52%                                 |
| Breast, Her-2 negative | 67%                         | 66%                                 | 43%                             | 42%                                 |

Sex, age and race impact slightly on failure risk. The examples refer to approximately 55-60 years-old Caucasian females. The differences for male patients are in the order of 1-2%.

### Table 4 Prognostic value of recursive partitioning analysis (RPA) classes

| Reference           | Number of patients | RPA class I | RPA class II | RPA class III |
|---------------------|--------------------|-------------|--------------|---------------|
| Gaspar et al. 1997 [88] | 1200              | 7.1         | 4.2          | 2.3           |
| Lorenzoni et al. 2004 [89] | 110 (SRS)         | 27.6        | 10.7         | 2.8           |
| Franzin et al. 2009 [90] | 185 (SRS)         | 17.0        | 10.0         | 3.0           |
| Likhacheva et al. 2012 [91] | 251 (SRS)        | 38.8        | 9.4          | 2.8           |
| Zindler et al. 2013 [92] | 380 (SRS)         | 18.0*       | 10.0*        | 4.0*          |
| Sneed et al.        | 268 (SRS)         | 14.0        | 8.2          | 5.3           |
| 2002 [26]           | 301 (SRS + WBRT)  | 15.2        | 7.0          | 5.5           |

Median survival in months from different publications.

RPA class I: age <65 years, Karnofsky performance status ≥70, controlled primary tumor, no extracranial metastases.

RPA class II: all other patients.

RPA class III: Karnofsky performance status <70.

SRS: stereotactic radiosurgery, WBRT: whole-brain radiotherapy.

*Estimated from Kaplan-Meier graphs included in the publication.
(radionecrosis and grade 4 seizures, respectively). After SRS plus WBRT, 3 patients developed a radionecrosis and 3 signs of leukencephalopathy. The rate of actuarial failure at 1 year was 47% after combined treatment, but significantly greater at 76% after SRS alone (relative increase of 62%; p < 0.001). New lesions developed in 42 vs 64% (p = 0.003). The risk was significantly higher in patients presenting with 2-4 lesions before treatment, those with active extracranial metastases and those with PS 70-80. WBRT reduced the risk of failure at the site of SRS from 27% to 11% after one year (p = 0.002).

The highly cited randomized trial from the M.D. Anderson Cancer Center re-emphasized patient selection issues as critical for overall survival [25]. In this trial, patients with 1-3 newly diagnosed brain metastases were randomly assigned to SRS plus WBRT or SRS alone, and over an almost 7-year time frame, 58 patients were recruited and stratified by RPA class, number of brain metastases, and histology. The primary endpoint was neurocognitive function: measured as a 5-point drop compared with baseline in the Hopkins Verbal Learning Test–Revised (HVLT-R) total recall at 4 months. An interim analysis showed that there was a high probability (96%) that patients assigned to receive SRS plus WBRT were more likely to show a decline in learning and memory function at 4 months than patients assigned to receive SRS alone. Further, at 4 months there were four deaths (13%) in the group that received SRS alone, and eight deaths (29%) in the group that received SRS plus WBRT, and 73% of patients in the SRS plus WBRT group were free from CNS recurrence at 1 year, compared with 27% of patients who received SRS alone (p = 0.0003). These differences in early death bring into question the generalizability of the HVLT-R score results. It is well known that a general disease-related decline due to progression, especially in the pre-terminal phase will cause a significant drop in neurocognitive function, and its attribution to a single component, such as WBRT can be misleading. Another potential confounder in evaluating survival following SRS, with or without WBRT, is the initiation of systemic treatment after radiation. Moreover, several drug regimens are known to impact on brain function [93]. Ongoing studies evaluate hippocampal sparing WBRT, which aims at reducing dose to critical structures and thereby risk of function decline, while maintaining improved brain control [94,95]. In many clinical scenarios, acceptable approaches include SRS or SRS plus WBRT, as also summarized in an American Society for Radiation Oncology (ASTRO) guideline [14] and recent reviews [84,96].

Salvage SRS as reirradiation after whole-brain radiotherapy

The potential advantages of SRS as salvage treatment after WBRT were realized early during the development of SRS [97]. The RTOG completed a prospective phase 1 clinical trial (RTOG 90-05) of SRS in recurrent, previously irradiated primary brain tumors and brain metastases. This was a dose escalation trial, which included 100 patients with brain metastases after prior WBRT to a median dose of 30 Gy [22]. Eligible patients had received first-line radiotherapy at least 3 months prior to study entry, and in the study, the actual median interval was 17 months. Life expectancy was ≥3 months. Seventy-eight percent of patients had single lesions. Dose was determined by the maximum diameter of the tumor. Initial doses were 18 Gy for lesions ≤20 mm, 15 Gy for lesions measuring 21-30 mm, and 12 Gy for lesions measuring 31-40 mm. Dose was prescribed to the 50-90% isodose line, which was to encompass the entire enhancing target volume. The dose was escalated in 3 Gy increments providing there was not an excess of unacceptable toxicity. The trial eventually defined the maximum acutely tolerable SRS dose in this setting, except for lesions ≤20 mm where the dose was not escalated beyond 24 Gy because of investigators’ reluctance. While small lesions ≤20 mm can be treated with up to 24 Gy to the margin of the lesion, those that measure between 21 and 30 mm might receive 18 Gy, and those that measure between 31 and 40 mm 15 Gy. Median survival was 7.5 months. Long-term toxicity data for 64 brain metastases patients revealed four patients developed radionecrosis requiring operation 5-14 months after SRS. This study therefore provides tentative evidence that retreatment with SRS can produce extended survival, but the incidence of necrosis must be factored in.

More recent data were derived from a retrospective review of 106 patients irradiated for a median of 2 metastases (range, 1-12) with a median dose of 21 Gy (range, 12-24) prescribed to the 50% isodose [98]. With a median follow-up of 10.5 months, local control was 83% at 6 months and 60% at 1 year. Median progression-free survival was 6.2 months. Median overall survival was 11.7 months from salvage SRS, and 22 months from initial diagnosis. Comparable outcomes were achieved in another retrospective series that included 111 patients [99]. SRS doses were usually prescribed according to the RTOG 90-05 guidelines. Median survival was 9.9 months. Twenty-five percent of patients developed further local progression in spite of salvage SRS. Poorer local control was observed in lesions >2 cm, which usually had been treated with lower radiation doses. Caballero et al. analyzed 310 patients [100]. The median number of brain metastases was 3, and interval from WBRT to SRS 8 months. The median survival was 8.4 months overall and 12.0 vs. 7.9 months for single vs. multiple lesions (p = 0.001). There was no relationship between number of lesions and survival after excluding patients with single metastases. Retrospective population-based data from Canada suggested that salvage SRS after WBRT was not associated with compromised survival
compared to immediate boost SRS [101]. Only preliminary experience with small numbers of patients exists for salvage SRS after first-line SRS [102]. No definitive conclusions regarding long-term safety have yet been published.

Prognostic staging systems

Patients with brain metastases have always presented with a variable spectrum of number, size and location of lesions, with different pattern and activity of extracranial disease, and with a wide range of comorbidities and PS. Estimation of prognosis is possible by using developed staging systems (Table 4) [41,43,88,89]. For example the RTOG developed the first RPA to define 3 classes of patients with statistically different predicted survival [88]. Other systems for predicting survival include the score index for radiosurgery (SIR) [43], basic score for brain metastases (BSBM) [89], and diagnosis-specific graded prognostic assessment (DS-GPA) score [41]. The latter is an increasingly used 4-tiered system that provides survival outcomes for patients with lung, breast, kidney and gastrointestinal cancers as well as malignant melanoma. These patients were treated with a variety of different approaches including but not limited to SRS. Their data were also used to create a prognostic nomogram [103]. In a recent study, symptomatic patients had an increased hazard for all-cause mortality (hazard ratio, 1.4) and were more likely to experience neurologic death after SRS (42% vs 20%, p < 0.0001) [104]. Relative to asymptomatic patients, symptomatic patients required more craniotomies (43% vs 5%, p < 0.0001) and were more likely to have RTOG grade 3 and 4 post-treatment symptoms (24% vs 5%; p < 0.0001).

Conclusions

SRS results in a high probability of treated-lesion control and, when adhering to typical dose/volume recommendations, a low normal tissue complication probability. However, SRS as sole first-line treatment carries a risk of failure in non-treated brain regions. SRS might also be prescribed as salvage treatment in patients relapsing despite previous SRS and/or WBRT. An optimal balance between intracranial control and side effects requires continued research efforts. Such efforts are also necessary to integrate new systemic treatments and/or stereotactic body radiotherapy, which aim at prolonged extracranial disease control.

Competing interest

The authors declare that they have no competing interests.

Authors’ contributions

CN participated in the design of the study and extraction of the references. All authors helped to review the references and draft the manuscript. All authors read and approved the final manuscript.

Author details

1Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway. 2Department of Radiation Oncology, University Hospital Freiburg, 79106 Freiburg, Germany. 3Department of Radiation Oncology, University of Colorado, 80045 Aurora, CO, USA.

Received: 25 April 2014 Accepted: 9 July 2014
Published: 12 July 2014

References

1. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H: Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer 2011, 117:2505–2512.
2. Shehata WM, Hendrickson FR, Hindo WA: Rapid fractionation technique and re-treatment of cerebral metastases by irradiation. Cancer 1974, 34:257–261.
3. Kurup P, Reddy S, Hendrickson FR: Results of re-irradiation for cerebral metastases. Cancer 1988, 66:2587–2589.
4. Nieder C, Milas I, Ang WK: Tissue tolerance to reirradiation. Semin Radiat Oncol 2000, 10:200–209.
5. Leksell L: The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951, 102:316–319.
6. Gutin PH, Bernstein M: Stereotactic interstitial brachytherapy for malignant brain tumors. Prog Exp Resour 1984, 28:166–182.
7. Leksell DG: Stereotactic radiosurgery. Present status and future trends. Neurol Res 1987, 9:60–68.
8. Colombo F, Benedetti A, Pozza F, Zanardo A, Avanzo RC, Chiareg G, Marchetti C: Stereotactic radiosurgery utilizing a linear accelerator. Appl Neurophysiol 1985, 48:133–146.
9. Greitz T, Lax I, Bergström M, Arntz J, Berggren BM, Blomgren H, Boëthius J, Lindqvist M, Ribe T, Steiner L: Stereotactic radiation therapy of intracranial lesions. Methodologic aspects. Acta Radiol Oncol 1986, 25:81–89.
10. Stumm V, Kober B, Höver KH, Schlegel W, Boesecke R, Pastry O, Hartmann GH, Schabbert S, zum Winkel K, Kunze S: Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. Int J Radiat Oncol Biol Phys 1987, 13:279–282.
11. Lutz W, Winston KR, Maleki N: A system for stereotactic radiosurgery with a linear accelerator. Int J Radiat Oncol Biol Phys 1988, 14:373–381.
12. Nieder C, Astner ST, Grosu AL: Glialblastoma research 2006-2010: a pattern of citation and systematic review of highly cited articles. Clin Neurol Neurosci 2012, 114:1207–1210.
13. Nieder C, Andratschke NH, Grosu AL: Increasing frequency of reirradiation studies in radiation oncology: systematic review of highly cited articles. Am J Cancer Res 2013, 3:152–158.
14. Tsao MN, Aref AM, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006, 295:2483–2491. Cited 527 times.
20. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiosurgery alone for patients with multiple brain metastases. J Neurosurg 1999, 82(5):476–484. Cited 116 times.

21. Flickinger JC, Kondziolka D, Lunsford LD, Coffey R, Goodman ML, Shaw EG, Hudsions RW, Weimer R, Harsh GR, Sneed PK, Larson DA: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994, 27:797–802. Cited 445 times.

22. Shaw E, Scott C, Souhami L, Dinapoli R, Kline RL, Loeffler JS, Faman N: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000, 47:291–296. Cited 393 times.

23. Alexander E III, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooi HM, Loeffler JS: Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 1995, 87:34–40. Cited 377 times.

24. Auchter RM, Lamond JP, Alexander E III, Buatti JM, Chappell R, Friedman WA, Kinsella TJ, Levin AB, Gelman RS, Loeffler JS: A new prognostic index for predicting failure of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 1996, 35:27–35. Cited 444 times.

25. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 1994, 27:797–802. Cited 445 times.

26. Sneed PK, Sperduto PW, Chao ST, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiversb J, Chang V, Kinsella TJ, Sperduto CM, Mehta M: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655–661. Cited 155 times.

27. Velmahos GT, Suh JH, Kameyama K, Tanaka H, Toyoda T, Mekada Y, Kamada T, Suga Y, Sone S, Iida K, Tada H: Stereotactic radiosurgery versus radiosurgery plus whole-brain radiotherapy for the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003, 55:116–119. Cited 155 times.

28. Sperduto PW, Chao ST, Luo X, Suh J, Roberge D: A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 2003, 55:116–119. Cited 155 times.

29. Cito F, Senigaglia R, Maggi E, Chiapella A, Castorina D, Bellia S, Giglio D, Gulisano M, Pastore F, Roviti L, Zambetti M, Martinelli G, Marongiu M, Salomoni F, De Stefano V, Riva R, Busacca P, Benzi G, Manara F, Berti F, Fumagalli G, Valvassori P, Carlini AM, Benassi A, Tatarelli R: Neurocognition in patients with brain tumors and brain metastases: Initial report of Radiation Therapy Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2003, 55:337–346. Cited 146 times.

30. Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, King VI, Lunsford LD, Kinsella TJ, Roper JC, Mc Kee D, Jho HD, Loeffler JS: Stereotactic radiosurgery versus radiosurgery plus whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999, 43:549–558. Cited 286 times.

31. Tschida A, Debuzios J, Loehr F, Fuss M, Rhein B: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998, 16:3563–3569. Cited 229 times.

32. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2002, 55:519–526. Cited 286 times.

33. Sneed PK, Lamborn KR, Fornasier JM, McDermott MW, Chang S, Park E, Gutin PH, Phillips TL, Wara WM, Larson DA: Radiosurgery for brain metastases: Is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999, 43:549–558. Cited 286 times.

34. Cited 137 times.

35. Cited 122 times.

36. Cited 121 times.

37. Muacevic A, Kreth FW, Horstmann GA, Schmid-Elsaesser R, Wowra B, Steiger J, Gref M, Lippold O, Hentschel G, Lauenroth W, Kremer C, Mader K, Welke F, Nolte-Oelsner E, Vahlensieck M, Opitz O, Lanz U, Froba W, Herrmann C, Schmiedt H, Nieder C: The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. J Clin Oncol 2001, 19:191–197. Cited 161 times.

38. Cited 122 times.

39. Cited 122 times.

40. Cited 122 times.

41. Cited 122 times.

42. Cited 122 times.

43. Cited 122 times.

44. Cited 122 times.

45. Cited 122 times.

46. Cited 122 times.

47. Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD: Stereotactic radiosurgery for brain metastases from renal cell carcinoma. Cancer 1998, 83:344–353. Cited 137 times.

48. Chidel MA, Suh JH, Reddy CA, Chao ST, Lundbeck MF, Barnett GH: Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 2000, 47:993–999. Cited 129 times.

49. Breneman JC, Warnick RE, Albright RE, Kukiatinant N, Shaw J, Armin D, Tew JR: Stereotactic radiosurgery for the treatment of brain metastases: Results of a single institution series. Cancer 1997, 79:551–557. Cited 127 times.

50. Shaw E, Scott C, Souhami L, Dinapoli R, Bahary JP, Kline R, Wharam M, Negri LS, Murray MA, Yung WK, Kimball F, Marcoux D, Tew JR: Stereotactic radiosurgery for treatment of recurrent primary brain tumors and brain metastases: Initial report of Radiation Therapy Oncology Group protocol 90-05. Int J Radiat Oncol Biol Phys 1996, 33:647–654. Cited 125 times.

51. Hasegawa T, Kondziolka D, Flickinger JC, Germanwalla A, Lunsford LD, Adler JR, Gutin PH, Tabar V, Piepmeier JM, Petrovic Z: Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy? Neurosurgery 2003, 52:1318–1326. Cited 123 times.

52. Definger SE, Huhn JL, Patchell RA, St Clair WH, Stroobants JM, Meigoni A, Sanders M, Young AB: Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: Results and implications. Int J Radiat Oncol Biol Phys 2002, 52:333–338. Cited 122 times.

53. Nedzi LA, Kooi H, Alexander E III, Gelman RS, Loeffler JS: Variables associated with the development of complications from radiosurgery of intracranial tumors. Int J Radiat Oncol Biol Phys 1991, 21:591–599. Cited 121 times.
Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir 2000, 142(6):621–636. Cited 108 times.

65. Coffey RJ, Flickinger JC, Bissonette DJ, Lunsford LD: Image fusion for stereotactic radiosurgery and radiosurgery treatment planning. Int J Radiat Oncol Biol Phys 1994, 28:1229–1234. Cited 112 times.

66. Schöggel A, Kitz K, Reddy M, Wolfsberger S, Schneider B, Dieckmann K, Ungersböck K: Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of brain metastases. Acta Neurochir 2000, 142(6):621–636. Cited 108 times.

67. Lavine SD, Petrovich Z, Cohen-Gadol AA, Masri LS, Morton DL, O’Malley RM: The cost effectiveness of the technique. Int J Radiat Oncol Biol Phys 2014, 88:130–136.

68. Aralar A, Modlin LA, Choi CY, Adler JR, Gibbs IC, Chang SD, Harsh GR 4th, Li G, Nagpal S, Hanlon A, Solty’s SG: Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 2013, 87:713–718.

69. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yanamaka K, Sato Y, Jokura H, Yamao N, Kanai O, Kanesa H, Morikita M, Suzuki K, Yoda I, Iwai Y, Hayashi M, Onishi H, Gondo M, Sato M, Akimitsu T, Kubo K, Nukichi T, Shibasaki H, Goto T, Takashima M, Mori Y, Takakura K, Saeki N, Kunieda E: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0001): A multi-institutional prospective observational study. Lancet Oncol 2014, S1470-2045(14)70061-0. doi:10.1016/S1470-2045(14)70061-0.

70. Ayala-Peacock DN, Peiffer AM, Lucas JT, Isom S, Kuremsky JG, Urbanic JJ, Berge D, Collette S, Collette L, Mueller RP: Best supportive care in patients with brain metastases and adverse prognostic factors: development of improved decision aids. Support Care Cancer 2013, 21:2671–2678.

71. Nieder C, Norum J, Dalhaua A, Aandahl G, Engjahrkiere J: Best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis 2013, 30:723–729.

72. Sperduto PW, Wang M, Robbins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami MD, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP: A phase 3 trial of whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 2014, 3:CD009454.

73. Nieder C, Norum J, Dalhaua A, Aandahl G, Pawinski A: Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis 2013, 30:723–729.
89. Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vander Linden B, Van Houtte P, Brotchi J, Lewiwer M: Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004, 60:218–224.

90. Franzin A, Snider S, Piccotti P, Bolognesi A, Serra C, Vmercani A, Passarini O, Montini P: Evaluation of different score index for predicting prognosis in gamma knife radiosurgical treatment for brain metastasis. Int J Radiat Oncol Biol Phys 2009, 74:707–713.

91. Likhacheva A, Pinnix CC, Parikh N, Allen PK, Guha-Thakurta N, McAleer M, Sulman EP, Mahajan A, Shiu A, Luo D, Chiu M, Brown PD, Prabhu SS, Chang EL: Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone. J Neurosurg 2012, 117:38–44.

92. Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagervuuf FJ: The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol 2013, 106:370–376.

93. Dutta V: Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther 2011, 7:264–269.

94. Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Nyazi M: Hippocampal sparing in whole-brain radiotherapy: A review. Strahlenther Onkol 2014, 190:337–341.

95. Prokić V, Wiedemann N, Fels F, Schmucker M, Nieder C, Grosu AL: Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys 2013, 85:264–270.

96. Patel CG, Piccola K, Sarmiento JM, Garg SK, Bryant A, Black KL: Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev 2012, 9, CD006121.

97. Ammirati M, Cobbis CS, Linsky ME, Paleologos NA, Ryken TC, Bunt SH, Asher AL, Loeffer JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McCormick M, Mehta MP, Mikkelsen T, Olson JJ, Pathell RC, Kalkanis SN: The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:85–96.

98. Kurtz G, Zadeth G, Gingras-Hill G, Miller BJ, Lapierriere NJ, Bernstein M, Jiang H, Ménard C, Chung C: Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection. Int J Radiat Oncol Biol Phys 2014, 88:137–142.

99. Chao ST, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Neyman G, Reuther AM, Suh JH: Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer 2008, 113:2198–2204.

100. Caballero JA, Sneed PK, Lamborn KR, Ma L, Denduluri N, Nakamura JL, Barani U, McCormick M: Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys 2012, 83:303–309.

101. Hsu F, Kouhestani P, Nguyen S, Cheung A, McKenzie M, Ma R, Toyota B, Kurtz G, Zadeh G, Gingras-Hill G, Millar BA, Laperriere NJ, Bernstein M, Jiang H, Ménard C, Chung C: Salvage radiosurgery for brain metastases after whole brain radiotherapy. Radiother Oncol 2013, 108:128–131.

102. Kim DH, Schultheiss TE, Radany EH, Badie B, Pezner RD: Clinical outcomes of patients treated with a second course of stereotactic radiosurgery for locally or regionally recurrent brain metastases after prior stereotactic radiosurgery. J Neurooncol 2013, 115:37–43.

103. Bamholtz-Sloan JS, Yu C, Sloan AE, Vengepechea J, Wang M, Dignam JJ, Vogelbaum MA, Sperduto PW, Mehta MP, Machtay M, Kattan MW: A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 2012, 14:910–918.

104. Lester SC, Takeda GB, Kuremsky JG, Lucas JT, Ayala-Peacock DN, Randolph DM 2nd, Boulard JD, Laxton AW, Tatter SB, Chan MD: Clinical and economic outcomes of patients with brain metastases based on symptoms: an argument for routine brain screening of those treated with upfront radiosurgery. Cancer 2014, 120:433–441.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Cite this article as: Nieder et al.: Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiotherapy Oncology 2014 9:155.